Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating.
The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position in the competitive landscape of antibody-drug conjugates (ADCs) to treat extensive-stage small cell lung cancer (ES-SCLC).
The recent update from the World Conference on Lung Cancer exhibited Merck’s I-DXd as the holder of considerable first-to-market advantage, attributed to the more globally diverse and larger patient population in Merck & Co., Inc.’s (NYSE:MRK) studies. According to the analyst, this supports their plans for accelerated approval.
Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.
Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
